Condition
Cutaneous Metastatic Melanoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Not Yet Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06870994Not ApplicableNot Yet RecruitingPrimary
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
NCT06894407Not ApplicableNot Yet RecruitingPrimary
Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma
NCT03928275Phase 2WithdrawnPrimary
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
Showing all 3 trials